NCT03102619 (WARD) is a clinical trial in Abdominal Cancer, sponsored by Bispebjerg Hospital.

Who is sponsoring NCT03102619?

NCT03102619 is sponsored by Bispebjerg Hospital.

What condition does NCT03102619 study?

NCT03102619 studies Abdominal Cancer, Postoperative Complications, Respiratory Complication, Circulatory; Complications.

Is NCT03102619 still recruiting?

NCT03102619 is currently completed. Last updated 18 January 2018.

Last reviewed 2018-01-18 · How we verify

NCT03102619: WARD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Wireless Assessment of Respiratory and Circulatory Distress; A Pilot Study

Completed Last updated 18 January 2018

What this trial tests

trial in Abdominal Cancer in 50 participants. Completed in 1 July 2017.

Timeline

23 March 2017

Primary endpoint
1 July 2017

1 July 2017

Quick facts

Lead sponsor	Bispebjerg Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	23 March 2017
Primary completion	1 July 2017
Estimated completion	1 July 2017
Sites	2 locations across Denmark

Conditions studied

Abdominal Cancer — all drugs for Abdominal Cancer →
Postoperative Complications — all drugs for Postoperative Complications →
Respiratory Complication — all drugs for Respiratory Complication →
Circulatory; Complications — all drugs for Circulatory; Complications →

Sponsor

Bispebjerg Hospital

Who can join

65 and older, any sex, with Abdominal Cancer or Postoperative Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postoperative observation of patients is based on the Early Warning Score (EWS). By using continuous wireless monitoring of vital parameters it may be possible to predict the risk of complications after abdominal cancer surgery. The object of this pilot study is to test the equipment and methods for the next phases. Patients will be monitored for 4 days postoperatively and data is analyzed retrospectively. Vital parameters are monitored with ECG, blood pressure monitor and pulseoximetry. In the analysis the investigators will compare the results from the continuous monitoring to the measurements made by the nurses and registered in the EWS. The primary outcomes for the pilot study are the frequency of measurements resulting in a single parameter score of 3 according to the EWS algorithm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Abdominal Cancer

Currently open trials in the same condition.

NCT05903430 — A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION) · recruiting
NCT05219058 — Reconstruction in Extended MArgin Cancer Surgery · recruiting
NCT00493688 — A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes · recruiting

Other Bispebjerg Hospital trials

Trials by the same sponsor.

NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
NCT07096648 — Alert Burden When Monitoring Patients at Home · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03102619 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
Last refreshed: 18 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03102619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing